Related by context. All words. (Click for frequent words.) 70 PLK1 SNALP 69 ALN PCS 67 Pivotal Phase III 67 IL# PE#QQR 67 PEG SN# 66 Perifosine 66 Allovectin 7 R 66 Azedra 65 SAR# [004] 65 XL# XL# 65 Phase 2b Clinical Trial 65 HDAC Inhibitor 65 MGCD# [001] 65 Voreloxin 65 Panzem R 65 FOLOTYN ® 65 PXD# 65 apaziquone 65 Onco TCS 65 Solazed TM 65 CD# CEA 65 MEK Inhibitor 65 Amrubicin 65 CORLUX CORT # 65 IMC #B 65 Daclizumab 65 Meets Primary Endpoint 64 Panzem R NCD 64 Allovectin 7 r 64 XYOTAX TM 64 TELINTRA 64 UPLYSO 64 LEP ETU 64 severe hypercholesterolemia 64 AQ4N 64 ALN HPN 64 ASONEP 64 telomerase therapeutic 64 Romidepsin 64 L BLP# 64 FUSILEV ® 64 NDA Submission 64 CINTREDEKIN BESUDOTOX 64 OvaRex R 64 Tezampanel 64 Personalized Immunotherapy 64 Bezielle 64 MKC# MT 64 Ridaforolimus 63 Myrexis 63 talactoferrin 63 Phase 2a Clinical Trial 63 Initiates Phase III 63 MCSP respectively 63 #D#C# 63 JAK inhibitor 63 Phase IIb Clinical Trial 63 Ozarelix 63 TOCOSOL Paclitaxel 63 Phase III Trials 63 Tamibarotene 63 Civacir 63 SinuNase TM 63 HGS ETR1 63 huC# DM4 63 IgG1 monoclonal antibody 63 Cetrorelix 63 HCV protease inhibitor 63 ALN TTR 63 Hsp# Inhibitor 63 AP# [003] 63 Genasense ® 63 Onconase 63 oral prodrug 63 pan HDAC inhibitor 63 Pivotal Phase 63 Completes Patient Enrollment 63 EOquin TM 63 ZADAXIN ® 63 MEK inhibitor 63 IAP inhibitors 63 Xanafide 63 Initiate Phase 63 Marqibo TM 63 orally administered inhibitor 63 Phase IIb Trial 63 vosaroxin 63 TKB# 63 HCD# [002] 63 PDE4 inhibitor 63 Cintredekin Besudotox 63 HGS ETR2 63 alvespimycin 63 XL# anticancer compounds 63 TRANSDUR Sufentanil 63 volociximab 62 phase IIb clinical 62 Virulizin R 62 registrational trial 62 elotuzumab 62 Archexin 62 Neulasta ® 62 deforolimus 62 Preclinical studies suggest 62 EndoTAG TM -1 62 Pivotal Trial 62 RhuDex ® 62 tamibarotene 62 Ofatumumab 62 Apaziquone 62 proteasome inhibitor 62 AVONEX ® 62 PKC# 62 Golimumab 62 Drug Candidate 62 Gleevec Glivec 62 forodesine 62 MOVIPREP R 62 Azedra TM Onalta TM 62 belinostat 62 oral proteasome inhibitor 62 Bicifadine 62 Patient Enrollment 62 Presents Preclinical Data 62 Pimavanserin 62 oncolytic virus therapies 62 Successfully Completes Phase 62 Exelixis XL# 62 Zemiva TM 62 HepeX B 62 Phase IIa clinical trials 62 Dalbavancin 62 ARRY # 62 rNAPc2 62 THALOMID 62 TREANDA 62 Eligard R 62 BAY #-# 62 Troxatyl 62 Evoltra ® 62 velafermin belinostat 62 BARACLUDE R 62 OXi# 62 ORENCIA ® 62 MORAb 62 targeted radiotherapeutic 62 cMET 62 ridaforolimus 61 INCB# [001] 61 Immunotherapeutic 61 receptor tyrosine kinase inhibitor 61 interferon gamma 1b 61 Phase III Clinical Trial 61 TYZEKA 61 Bortezomib 61 EndoTAG TM 61 TKM ApoB 61 MEK inhibitors 61 Aflibercept 61 Preclinical Data 61 NEBIDO R 61 Ecallantide 61 Phenoptin 61 Initiates Clinical 61 registrational studies 61 Gemzar ® 61 Milestone Payment 61 Phase III Trial 61 Innovive 61 molecular imaging radiopharmaceutical 61 adecatumumab MT# 61 Onalta 61 Brentuximab Vedotin SGN 61 RNAi Therapeutic 61 RITUXAN 61 IMiDs 61 cinacalcet HCl 61 Solazed 61 Granulocyte Colony Stimulating Factor 61 CCX# 61 Talactoferrin 61 Iloperidone 61 Budesonide MMX 61 JAK2 Inhibitor 61 Presents Preclinical 61 novel histone deacetylase 61 PDX pralatrexate 61 XL# XL# XL# 61 atacicept 61 Hematide ™ 61 Cloretazine ® 61 Milestone Payments 61 lintuzumab SGN 61 Receives Orphan Drug Designation 61 PNP inhibitor 61 mitogen activated ERK kinase 61 Solazed ™ 61 bardoxolone 61 Vicriviroc 61 Lenocta TM 61 Clolar ® 61 Allovectin 7 61 Sapacitabine 61 SonoLysis 61 erlotinib Tarceva ® 61 CR# vcMMAE 61 Pirfenidone 61 MNTX 61 Genasense R 61 JAK1 61 RGB # 61 telomerase inhibitor drug 61 vaccine GRNVAC1 61 mGluR5 negative 61 Initiates Phase II 61 Elagolix 61 ONTAK 61 Supplemental Biologics License Application 61 ospemifene 61 subcutaneous formulation 61 MDV# 61 TRISENOX ® 61 MT# MEDI 61 investigational humanized monoclonal antibody 61 IMA# 61 Rebif ® 61 ANYARA 61 RECOTHROM R 61 Phase III Pivotal 61 Phase III Clinical Trials 61 ularitide 61 Pradefovir 61 oral picoplatin 61 PRN FDA Approves 61 histone deacetylase HDAC inhibitor 61 telaprevir VX 61 Nexavar ® 61 oncology indications 60 Recombinant Human 60 Trial Evaluating 60 EOquin 60 Pralatrexate 60 Investigational Compound 60 teduglutide 60 radiation sensitizer 60 Clinical Trial Results 60 Dapagliflozin 60 ganetespib 60 epigenetic therapies 60 Entereg R 60 TAFA# 60 Indaflex TM 60 epothilones 60 TRAIL receptor antibodies 60 dacetuzumab SGN 60 class anticancer quinolone 60 Cethromycin 60 dextromethorphan quinidine 60 squalamine 60 Phase #b/#a clinical 60 Asentar TM 60 Initiate Clinical Trial 60 EGFR HER2 60 LibiGel ® 60 metaglidasen 60 docetaxel Taxotere ® 60 fosbretabulin 60 ZOLINZA 60 Panitumumab 60 trastuzumab DM1 60 Orphan Drug designations 60 Alnylam #x# 60 eniluracil 60 R sorafenib tablets 60 FavId 60 ELND# 60 YONDELIS 60 CYC# 60 Lenocta 60 Present Preclinical Data 60 ZYBRESTAT 60 LEUKINE 60 LE SN# 60 ALN TTR# 60 Phase #/#a trial 60 docetaxel Taxotere R 60 ONCONASE 60 XL# XL# XL# XL# 60 induced macular edema 60 Panzem 60 ZEFTERA TM Zevtera TM 60 PentaStaph 60 novel VDA molecule 60 HCV protease 60 GVAX R 60 Urokinase 60 histone deacetylase inhibitor 60 TELCYTA 60 MAGE A3 ASCI 60 Campath ® 60 DOS# 60 Ixempra 60 Xeloda ® 60 Phase IIb trials 60 HER2 positive metastatic breast 60 ALN VSP 60 IV APAP 60 Phase 1b Clinical Trial 60 axitinib 60 beta 1a 60 PrevOnco 60 Aurexis 60 trastuzumab DM1 T DM1 60 FTY# 60 CD# monoclonal antibody 60 LY# [003] 60 Randomized Phase 60 Onalta ™ 60 Files Investigational 60 Achieves Primary Endpoint 60 bafetinib 60 ISTODAX 60 Bremelanotide 60 Orphan Drug Status 60 Carfilzomib 60 Cutaneous T 60 Stimuvax R 60 tiapamil 60 Omacetaxine 60 PANVAC VF 60 Ixabepilone 60 lymphoid malignancies 60 INSPIRE Trial Phase III 60 Proellex TM 60 ZEVALIN ® 60 Pivotal Study 60 Intravenous CP 59 Æterna Zentaris 59 CCR9 antagonist 59 PI3K/Akt pathway inhibitor 59 Combination REOLYSIN R 59 Phase IIIb clinical 59 Elotuzumab 59 hypoxia activated prodrug 59 Presents Positive 59 voreloxin 59 oral ridaforolimus 59 REBETOL combination therapy 59 5 HT6 59 Cleviprex TM clevidipine 59 Pruvel 59 Telik logo TELINTRA 59 Tarceva TM 59 evaluating satraplatin 59 Hedgehog pathway inhibitor 59 StemEx 59 Dacogen injection 59 seliciclib CYC# 59 Aurora Kinase 59 monoclonal antibody conjugated 59 R lenalidomide 59 PEG Interferon lambda 59 Phase 2b Trial 59 highly selective inhibitor 59 CIMZIA TM 59 satraplatin 59 RELISTOR ® 59 Vidaza R 59 ADP receptor antagonist 59 AzaSite Plus 59 Icatibant 59 danoprevir 59 AEG# 59 Raptiva ® 59 Antitumor Activity 59 Satraplatin 59 ABILIFY ® 59 EZN 59 Irinotecan 59 IMC A# 59 PF # [001] 59 HspE7 59 anticancer compound 59 TRISENOX 59 Exherin 59 MOZOBIL 59 candidate AQ4N 59 ThermoDox R 59 Trofex TM 59 darapladib 59 Marqibo 59 Zenvia Phase III 59 Initiates Clinical Trial 59 evaluating tivozanib 59 ocrelizumab 59 torezolid phosphate 59 immunotherapeutic agent 59 PSMA ADC 59 Darinaparsin 59 Metastatic Melanoma 59 Glufosfamide 59 ABILIFY R 59 Receives Fast Track 59 dasatinib Sprycel ® 59 tezampanel 59 veltuzumab 59 Oncaspar 59 JAK Inhibitor 59 EVIZON TM squalamine lactate 59 Xcytrin R 59 LymphoStat B TM 59 Seliciclib 59 apoptosis inducer 59 MAXY alpha 59 Ganite ® 59 StaphVAX R 59 EVIZON TM 59 leading oral taxane 59 oral isoform selective HDAC 59 Temsirolimus 59 Mipomersen 59 refractory chronic lymphocytic 59 Azedra ™ 59 LUCASSIN 59 Crofelemer budesonide foam 59 SPRYCEL ® 59 Targeted Chemotherapy 59 Maribavir 59 Investigational Oral 59 CYT# potent vascular disrupting 59 Fast Track Status 59 hoFH 59 AIMM trial 59 Hedgehog Pathway Inhibitor 59 Amigal 59 Receives Milestone Payment 59 Azixa 59 VEGF Trap 59 Reports Preclinical Data 59 VISICOL R 59 Trodusquemine MSI 59 eltrombopag 59 PRTX 59 Prednisporin 59 targeting CD# 59 hormone LHRH antagonist 59 Kinase Inhibitor 59 orally bioavailable 59 Zerenex ™ 59 Intravenous Human 59 BiovaxID TM 59 R#/MEM # 59 investigational monoclonal antibody 59 ® bortezomib 59 registrational 59 AnGes 59 Laquinimod 59 perifosine 59 Hsp# inhibitors 59 XL# [003] 59 PRECISE trial 59 trastuzumab Herceptin R 59 Anti Tumor 59 liposomal formulation 59 RAPTIVA 59 ATryn ® 59 amrubicin 59 selective modulator 59 Ambrisentan 59 RELOVAIR ™ 59 Initiates Enrollment 59 Urocidin TM 59 R bortezomib 59 RAPTIVA R 59 forodesine hydrochloride 59 ORENCIA R 59 gefitinib Iressa 59 MKC# MKC# PP 59 Pafuramidine 59 Prodrug 59 non nucleoside HCV 59 BRIM2 59 2 methoxyestradiol 59 HCV protease inhibitors 59 Anticancer Compound 59 Triolex 59 sorafenib tablets 59 Peginterferon alfa 2b 59 faropenem 59 Onyx Pharmaceuticals Announces 59 Eculizumab 59 aflibercept 59 HCV polymerase 59 PRT# 59 Aurora kinase 59 Orally administered 59 KNS # 59 Cloretazine R VNP#M 59 OncoVEX GM CSF 59 OTC BB PVCT 59 ARIKACE ™ 59 recombinant biopharmaceutical 59 GATTEX TM 59 methylnaltrexone bromide 59 Vascular Disrupting Agent 59 drug conjugate 59 PS# [001] 59 DU #b 59 Zorbtive TM 59 darinaparsin ZIO 59 antibody MAb 59 Epratuzumab 59 Demonstrates Significant 59 ENZON 59 Guanilib 59 Clevudine 59 MAXY G# 59 acyclovir Lauriad R 59 Taiho Pharmaceutical 59 polymerase inhibitor 59 selective kinase inhibitor 59 Prolongs Survival 59 RNAi Therapeutics 59 tubulin inhibitor 58 NUEDEXTA ™ 58 estrogen receptor antagonist 58 non nucleoside inhibitor 58 Protexia R 58 Talabostat 58 CCX# B 58 Nippon Kayaku 58 including eniluracil ADH 58 Catena ® 58 PEG PAL 58 AEGR 58 cutaneous T 58 Receives Orphan Drug 58 investigational compounds 58 glucokinase activator 58 RDEA# 58 Factor VIIa 58 REMOXY POSIDUR ELADUR 58 XP# XP# 58 KRN# 58 ATL# [001] 58 Dextofisopam 58 Ceflatonin R 58 albinterferon alfa 2b 58 Methylnaltrexone 58 oral Hsp# inhibitor 58 octreotide implant 58 RIGScan CR 58 Inhalation Solution 58 IV Busulfex 58 Elesclomol 58 Initiates Phase 58 cancer immunotherapies 58 N acetylgalactosamine 6 58 drug pipeline TAFA# 58 Vidofludimus 58 Sulonex TM 58 celgosivir 58 HSP# inhibitor 58 Adnectin 58 PROSTASCINT R 58 samarium Sm 58 bevacizumab Avastin ® 58 product candidate Lpathomab 58 acetonide FA 58 PGL# 58 initiated Phase 1b 58 cetuximab Erbitux R 58 AAG geldanamycin analog 58 HepeX B TM 58 SARMs 58 InterfeRx 58 alvimopan 58 enzastaurin 58 GATTEX ® 58 Advanced Renal Cell 58 endothelin receptor antagonists 58 vidofludimus 58 FOR FURTHER INFORMATION ABOUT 58 thymalfasin 58 DPX Survivac 58 humanized anti 58 dacetuzumab 58 Tesamorelin 58 Antibody Drug Conjugate 58 rxRNA 58 Rotarix ® 58 Lubiprostone 58 ISTODAX ® 58 ISIS # 58 XmAb ® 58 Neupogen ® 58 #ME# 58 palifosfamide Zymafos TM 58 PEGylated Fab fragment 58 Granted Orphan Drug 58 candidates Azedra TM 58 TACI Ig 58 systemically administered 58 Xcellerated T Cells 58 LymphoStat B belimumab 58 fostamatinib 58 Phase 2a Study 58 relapsed refractory multiple myeloma 58 LAF# 58 Phase Ib II 58 pentadentate logo R 58 cetuximab Erbitux 58 PhosLo 58 lumiliximab 58 small molecule tyrosine 58 Phase 2a clinical trials 58 Earns Milestone Payment 58 Systemic Delivery 58 bazedoxifene 58 INCB# [002] 58 Pazopanib 58 Phase 2a Trial 58 HuMax CD# 58 Allovectin 7 ® 58 Ganite R 58 Soliris eculizumab 58 Apoptone 58 Zerenex 58 Ophthotech 58 Cloretazine R 58 Surfaxin LS 58 HoFH 58 Tarsa Therapeutics 58 Arno Therapeutics 58 Celgosivir 58 ZADAXIN 58 Shigamabs ® 58 BLP# Liposome Vaccine 58 Pruvel ™ 58 Actimmune ® 58 Thalomid ® 58 SinuNase ™ 58 COLAZAL R 58 Rhucin ® recombinant 58 Commences Phase 58 oral dihydropyrimidine dehydrogenase DPD 58 novel DACH platinum 58 ProLindac TM 58 R#/MEM 58 panitumumab Vectibix 58 6R BH4 58 Reverset 58 Commence Phase 58 IFN Beta CTP 58 Serdaxin 58 vaccines oncolytic virus 58 Begins Dosing 58 Novel Oral 58 regadenoson 58 Zemiva TM Trofex TM 58 LymphoStat B 58 PREOS R 58 Chemophase 58 TASKi2 58 Submits NDA 58 galiximab 58 ASA# 58 oxymorphone ER 58 Poly ICR 58 Exherin TM 58 TBC# 58 vinca alkaloids 58 Alemtuzumab 58 ThermoDox ® clinical 58 AVE# 58 humanized monoclonal antibody 58 methylnaltrexone 58 GVAX ® 58 generation purine nucleoside 58 huN# DM1 58 rALLy 58 prokinetic agent 58 castrate resistant prostate cancer 58 successfully commercialize Iluvien 58 selective immunoproteasome inhibitor 58 Viprinex 58 ONCONASE R 58 Targeted Immunotherapy 58 peripherally acting 58 fipamezole 58 Ereska 58 MAb therapy 58 Leukine ® 58 TRANSDUR ® 58 lexidronam injection 58 Targretin 58 multicenter Phase III 58 2 inhibitor CYT# 58 aripiprazole Abilify 58 urocortin 2 58 CDK inhibitor 58 INTEGRILIN 58 Azedra TM 58 IMiDs R 58 Protexia ® 58 BiTE antibody 58 ApoB SNALP 58 Previously Treated 58 YONDELIS R 58 Oracea TM 58 SAR# [002] 58 REMOXY R 58 pradefovir 58 NPS NPS Pharmaceuticals 58 Myocet 58 Tesetaxel 58 Liprotamase 58 soluble tumor necrosis 58 Friedreich Ataxia FRDA 58 Diabetic Macular Edema 58 renin inhibitor 58 tezampanel NGX# 58 Squalamine 58 Lung Cancer Drug 58 generation Hsp# inhibitor 58 Fludara ® 58 ONX 58 Milatuzumab 58 tanespimycin 58 LE DT 58 Zoraxel 58 Kosan dependence 58 Sym# 58 Agenerase 58 Kyowa Kirin 58 Enzyme Replacement Therapy 58 Tanespimycin 58 Announces Poster Presentations 58 Ophena TM 58 HCV Protease Inhibitor 58 novel emulsion formulation 58 Argatroban 58 CINOD 58 highly purified pasteurized 58 Zolinza 58 Romiplostim 57 Tyzeka Sebivo 57 Pivotal Clinical Trial 57 Presents Positive Preclinical 57 Unit Dose Budesonide 57 Well Tolerated 57 Genz # 57 Phenserine 57 Plicera 57 pralatrexate injection folate analogue 57 adecatumumab 57 custirsen 57 vascular disrupting agents 57 novel immunomodulatory 57 DAVANAT R 57 miconazole Lauriad 57 Clofarabine 57 ATL# [002] 57 TRACON Pharmaceuticals 57 ZALBIN 57 POSIDUR TM ELADUR TM 57 Oracea ® 57 novel MetAP 2 57 VEGFR2 inhibitor 57 Spectrum Pharmaceuticals 57 Maxy G# 57 Randomized Phase II 57 Anti Tumor Activity 57 Fibrillex TM 57 NeoLipid R 57 BENLYSTA ® 57 telbivudine 57 compound PMX # 57 Azilect ® 57 HuLuc# 57 Sensipar R 57 PHX# 57 Biological License Application 57 investigational antiplatelet agent 57 substantially excreted 57 TRX1 57 Aganocide 57 Antiangiogenic 57 arsenic trioxide injection 57 AKT inhibitor 57 peginesatide 57 initiated Phase Ib 57 prostone 57 metastatic castrate resistant 57 TRISENOX R 57 Thiovir 57 IND enabling 57 tafamidis 57 FDA Accepts 57 elvucitabine 57 dependent kinase inhibitor 57 UVIDEM 57 oral taxane 57 Commercialization Agreement 57 synthetic retinoid 57 FOLFOX chemotherapy 57 LIVALO 57 antibody MT# 57 CAMPATH 57 metastatic colorectal 57 ixabepilone 57 TLK# 57 virus HCV protease inhibitor 57 BioNumerik 57 Combidex 57 REG1 Anticoagulation System 57 polymerase inhibitors 57 GW# [003] 57 Zoraxel TM 57 E1 INT TM 57 Specifid 57 relapsed multiple myeloma 57 Pegloticase 57 forodesine HCl 57 investigational compound 57 Asentar 57 clevudine 57 II Clinical Trial 57 pralatrexate 57 Investigational Treatment 57 Targretin capsules 57 Vivecon 57 HuMax EGFr 57 phase IIa clinical 57 Paraplatin ® 57 glufosfamide 57 Nasulin ™ 57 TRANSDUR ™ 57 Sangamo BioSciences Announces 57 Abiraterone acetate 57 catheter occlusion 57 polymer platinate 57 Initiates Phase 2b 57 Marketing Authorisation Application 57 R bendamustine hydrochloride 57 mitotic kinesins 57 Ocrelizumab 57 sodium glucose cotransporter 57 poly ADP ribose polymerase 57 Taxotere R 57 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 57 HGS ETR1 mapatumumab 57 Luteinizing Hormone Releasing Hormone 57 RenaZorb TM 57 PEGylated interferon beta 1a 57 Albugon 57 Ganciclovir 57 Excellarate 57 Tasimelteon 57 Azacitidine 57 Linjeta TM 57 sodium thiosulfate STS 57 BUPHENYL R 57 DURIN TM 57 Phase Ib clinical trials 57 GTC recombinant human 57 ABRAXANE TM 57 ATryn R 57 HuMax TAC 57 isoform selective 57 albiglutide 57 Exelixis compounds 57 PrevOnco ™ 57 lorvotuzumab mertansine 57 PROMACTA 57 Therapeutic Vaccine 57 INTEGRILIN ® 57 cutaneous T cell 57 AEterna Zentaris 57 Genentech Rituxan 57 Pivotal Phase II 57 highly selective adenosine 57 Phase 2b clinical trials 57 Cx# [002] 57 Telaprevir 57 HuMax CD4 57 Anturol TM 57 IMGN# 57 Submits Response 57 SYCREST 57 Cephalon Oncology 57 Akt inhibitor 57 T#I mutant 57 Lupus Nephritis 57 OvaRex ® MAb 57 RhuDex TM 57 Certolizumab 57 febuxostat 57 siRNAs targeting 57 alemtuzumab MS 57 agonistic human 57 MyVax R 57 zanolimumab 57 AZD# 57 PEG INTRON 57 Adentri 57 Testosterone Gel 57 ZEVALIN 57 Aplidin R 57 sarcoma melanoma 57 Files IND 57 Genasense ® oblimersen 57 metastatic hormone refractory 57 GLP toxicology studies 57 Locteron 57 product platforms AZX# 57 Phase 2b Study 57 vernakalant oral 57 Octreolin 57 PROVENGE ® 57 hematological cancers 57 selective androgen receptor modulator 57 Eloxatin ® 57 BEXXAR 57 LUCENTIS 57 relapsed leukemia 57 CoFactor 57 MPS IVA 57 Fx #A 57 Insegia 57 Fulvestrant 57 Factor Receptor 57 candidate deforolimus 57 Phase IIb clinical trials 57 ELACYT 57 diabetic neuropathic pain 57 pediatric acute lymphoblastic 57 oral deforolimus 57 Phase Ib 57 CIMZIA ™ 57 Perifosine KRX 57 allosteric modulator NAM 57 Neulasta R 57 human C1 inhibitor 57 Somatuline Depot 57 RNAi therapeutic targeting 57 Through Glycoscience 57 ADVEXIN 57 Aliskiren 57 mipomersen 57 chemotherapy induced neutropenia 57 Forodesine HCl 57 lenalidomide Revlimid R 57 L Annamycin 57 THR beta agonist 57 MTP inhibitor 57 CAELYX 57 CA4P 57 VentiRx Pharmaceuticals 57 Somatuline R Depot 57 Ventavis 57 Zenvia ™ 57 Anturol 57 Alfacell proprietary ribonuclease 57 lintuzumab 57 Taxotere ® 57 Phase IIa trials 57 ALKS 57 Serdaxin ® 57 Traficet EN 57 Monoclonal Antibody 57 Fludara 57 Kuvan R 57 MGd 57 RAPTIVA r 57 Testim R 57 ABL inhibitor 57 TMC# [002] 57 hyaluronidase enzyme 57 ® decitabine 57 MOR# 57 IPL# 57 BXT # 57 Harbor BioSciences 57 Frova ® 57 myelodysplastic myeloproliferative diseases 57 Rheumatoid Arthritis Drug 57 NVA# 57 generation nucleoside analog 57 Nasdaq ENZN 57 chimeric monoclonal antibody 57 XOMA 3AB 57 rhMBL 57 midstage clinical 57 Loramyc R 57 Anticancer Activity 57 Tß4 57 ALVESCO R 57 NKTR